-

NYSE American to Suspend Trading in Viveon Health Acquisition Corp. (VHAQ)

NEW YORK--(BUSINESS WIRE)--NYSE American LLC (“NYSE American” or the “Exchange”) announced today that the staff of NYSE Regulation has determined to suspend trading in the three securities enumerated below (“Securities”) of Viveon Health Acquisition Corp. (the “Company”) from NYSE American. The staff suspended trading in the Company’s Securities because the Listings Qualifications Panel (the “Panel”) of the Committee for Review of the Board of Directors of the Exchange (the “Committee”) had issued a decision in which it upheld the Exchange’s previously announced determination to delist the Company’s Securities.

Symbol

Description

VHAQ

Common Stock

VHAQU

Units

VHAQR

Rights

The Exchange previously announced on December 22, 2023 that it had commenced delisting proceedings with respect to the Company’s Securities that same day pursuant to Sections 119(b) and 119(f) of the NYSE American Company Guide because the Company failed to consummate a business combination (i) within 36 months of the effectiveness of its initial public offering registration statement, or (ii) such shorter period that the Company specified in its registration statement. The Company had the right to request a review of this delisting determination by the Panel.

The Company has a right to a review of the Panel’s decision to delist the Securities by the Committee by making a written request within 15 calendar days of the date of the Panel’s decision. The filing by the Exchange of an application with the Securities and Exchange Commission to delist the Securities is pending completion of all applicable procedures, including any appeal by the Company of the Panel’s decision.

Contacts

Company Contacts:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

NYSE Regulation


Release Versions

Contacts

Company Contacts:
Rom Papadopoulos, M.D.
Chief Financial Officer
T (404) 861-5393
E rom@viveonhealth.com

NYSE Contact:
NYSE Communications
PublicRelations-NYSE@ice.com

More News From NYSE Regulation

NYSE Group Consolidated Short Interest Report

NEW YORK--(BUSINESS WIRE)--NYSE today reported short interest as of the close of business on the settlement date of April 15, 2026. SETTLEMENT DATE EXCHANGE TOTAL CURRENT SHORT INTEREST TOTAL PREVIOUS SHORT INTEREST (Revised) NUMBER of SECURITIES with a SHORT POSITION NUMBER of SECURITIES with a POSITION >= 5,000 SHARES 04/15/2026 NYSE 17,363,958,102 17,648,394,291 2,880 2,606 04/15/2026 NYSE ARCA 2,225,622,986 2,336,811,859 2,582 1,750 04/15/2026 NYSE AMERICAN 914,879,343 893,347,701 311 25...

NYSE to Commence Delisting Proceedings Against QVC, Inc. (QVCC, QVCD)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the two securities enumerated below (“Securities”) of QVC, Inc. (the “Company”) from the Exchange. Trading in the Company’s Securities will be suspended immediately. Symbol Description QVCC 6.250% Senior Secured Notes due 2068 QVCD 6.375% Senior Secured Notes due 2067 NYSE Regulation reached its decision that the Compa...

NYSE to Commence Delisting Proceedings with Respect to Warrants of Perfect Corp. (PERF WS)

NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the warrants (“Warrants”) — ticker symbol PERF WS — each warrant exercisable for one Class A ordinary share at an exercise price of $11.50 of Perfect Corp. (the “Company”) from the NYSE. Trading in these Warrants on the NYSE will be suspended immediately. Trading in the Company’s Class A ordinary shares — ticker symbol...
Back to Newsroom